马来酸西布曲明(Sibutramine maleate) - 药物靶点：DAT x NET x SERT_在研适应症：神经性厌食症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

DAT x NET x SERT

作用方式

抑制剂

作用机制

多巴胺重摄取抑制剂、NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、5-羟色胺重摄取抑制剂

治疗领域

其他疾病

在研适应症

神经性厌食症

非在研适应症-

原研机构

Abbott Laboratories

在研机构

Abbott Laboratories

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2011-12-01),

神经性厌食症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H26ClN

InChIKeyUNAANXDKBXWMLN-UHFFFAOYSA-N

CAS号106650-56-0

查看全部结构式(2)

关联

16

项与马来酸西布曲明相关的临床试验

NCT00993421

/ Terminated临床2期

LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women

The purpose of this study is to determine if LY377604 + sibutramine work better than LY377604 or sibutramine alone in the treatment of obesity.

开始日期2009-10-01

申办/合作机构

Eli Lilly & Co.

NCT00914212

/ Completed临床1期

A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men

This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by sibutramine.

开始日期2009-05-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT01170364

/ Terminated临床4期IIT

Studying the Effects of Sibutramine on Eating Behavior

Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating behavior, cognitive functioning, and psychological functioning under sibutramine and placebo conditions.

开始日期2009-02-01

申办/合作机构

The New York State Psychiatric Institute

[+1]

100 项与马来酸西布曲明相关的临床结果

登录后查看更多信息

100 项与马来酸西布曲明相关的转化医学

登录后查看更多信息

100 项与马来酸西布曲明相关的专利（医药）

登录后查看更多信息

1,784

项与马来酸西布曲明相关的文献（医药）

2025-02-01·Talanta

Portable unibody semi-flow injection voltammetric sensor for on-site screening of illegal additive sibutramine in food supplements

Article

作者: Saisahas, Kasrin ; Limbut, Warakorn ; Wangchuk, Sangay ; Samoson, Kritsada ; Soleh, Asamee ; Promsuwan, Kiattisak ; Saichanapan, Jenjira

In this study, a simple, portable, unibody semi-flow injection system was coupled with a screen-printed electrode (SFI/SPE) for the on-site electrochemical screening of sibutramine (SBM) in food supplements. The SFI was fabricated by laser engraving acrylic plastic and was attached to a modified SPE with double-sided adhesive tape. The SPE was modified with a nanocomposite of nitrogen-doped graphene nanoflakes and carbon nanotubes synthesized using hydrothermal and ultrasonic methods. The morphological structure and electrochemical properties of the nanocomposite were thoroughly investigated. The portable SFI-SPE sensing system was designed to be interfaced with a smartphone. Sample solutions can be continuously injected into the sensing system using a plastic syringe and SBM is determined by square wave anodic stripping voltammetry, controlled by means of a smartphone. The developed sensing system displayed linear ranges from 0.010 to 10 μg mL⁻¹ and 10-60 μg mL⁻¹ with an LOD of 0.0035 μg mL⁻¹. The sensor delivered a response in a short time and demonstrated not only good reproducibility (RSDs ranging from 2.9 % to 4.9 % (n = 10)) and excellent resistance to interference but also high accuracy. The developed sensor was utilized for the screening and quantification of SBM in food supplements but the system could be used in a wider range of electrochemical (bio) sensor applications in the future.

2025-01-01·Endocrine Practice

Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide

Review

作者: Ur Rehman, Adeel ; Sarwar, Ayesha ; Fareed, Areeba ; Asif, Muhammad Iqbal ; Iftikhar, Zoha ; Vaid, Rayyan ; Ghanem, Laura

BACKGROUNDObesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, and Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Moreover, various surgical modalities, such as Roux-en-Y Bypass surgery, sleeve gastrectomy, intragastric balloons, biliopancreatic diversion with duodenal switch, laparoscopic adjustable gastric band, and vagal nerve blockade can be considered but are associated with numerous side effects and require careful monitoring. Consequently, there is a pressing need for novel anti-obesity treatments.METHODSThis comprehensive review was based on the available data to discuss the traditional pharmaceutical and surgical therapeutical strategies for obesity, going further to discuss tirzepatide's mode of action, its outcomes for obesity, and the associated side effects.RESULTSIn this landscape, tirzepatide, initially designed for type 2 diabetes management, emerges as a potential game-changer. Functioning as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, it not only addresses control but also introduces a fresh perspective on weight reduction. This review intricately explores tirzepatide's mechanism, dissecting insights from clinical studies and positioning it as a major force in obesity treatment.CONCLUSIONSIn the middle of significant shifts in obesity management, tirzepatide presents itself as a promising and cost-effective intervention. Its Food and Drug Administration approval marks a milestone in the realm of obesity therapeutics. Going beyond a recapitulation of findings, the conclusion emphasizes the imperative for ongoing exploration and vigilant safety monitoring in tirzepatide's application.

2025-01-01·Talanta

Identification of fenfluramine adulteration in slimming foods using a highly sensitive immunoassay

Article

作者: Yu, Xiaoqin ; Li, Zhaodong ; Wang, Yu ; Raza, Sayed Haidar Abbas ; Huang, Xin-an ; Huang, Xin-An ; Abbas Raza, Sayed Haidar ; Chen, Jiahong ; Zhang, Shiwei ; Qian, Zhenjie ; Lei, Hongtao ; Liu, Zhiwei ; Chen, Yanhong ; Zhenjie, Qian ; Pan, Kangliang

Fenfluramine, an appetite suppressant used for weight loss, can cause significant harm if overdosed. The unauthorized addition of fenfluramine to slimming foods has raised concerns. Currently, no rapid screening method is available for the quick detection of fenfluramine in the field. This study proposes six new haptens with varying spacer arm lengths and hydrophobicity, promising to elicit antibodies capable of being highly specific and strongly binding to fenfluramine. The study found that highly hydrophobic haptens with long spacer arms favored the generation of highly sensitive antibodies. Key interaction forces for antibody recognition of fenfluramine were revealed by intrinsic molecular mechanisms. Based on the above results, monoclonal antibody for fenfluramine was prepared and an ultrasensitive icELISA method with heterologous coating strategies was developed in slimming foods. The IC₅₀ of the method was 6.25 ng/mL, the linear detection range was 0.47-83.51 ng/mL and the detection limit was 0.10 ng/mL. Recovery rates in tea bags, tablets, capsules, coffee, and beverages ranged from 96.56 % to 108.90 %. The method was successfully applied to blind samples, showing strong correlation with HPLC-MS/MS results. Thus, the developed method is suitable for identifying fenfluramine adulteration in slimming foods.

100 项与马来酸西布曲明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A08AA10	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经性厌食症	韩国	Abbott Laboratories	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01170364 (CTgov)	临床4期	肥胖	14	Placebo+Sibutramine (Sibutramine)	構鹽淵醖鹹襯蓋餘醖醖(鹽衊簾構範鑰蓋窪鬱願) = 積觸選糧蓋蓋壓餘艱襯齋夢艱選蓋選壓願顧積 (遞蓋齋衊淵衊衊壓範齋, 獵鬱淵觸顧夢憲繭獵鏇 ~ 鹹繭鑰廠範糧簾淵艱選) 更多	-	2017-07-31
				Placebo+Sibutramine (Placebo)	構鹽淵醖鹹襯蓋餘醖醖(鹽衊簾構範鑰蓋窪鬱願) = 齋襯構壓獵齋構簾夢餘齋夢艱選蓋選壓願顧積 (遞蓋齋衊淵衊衊壓範齋, 糧餘簾製夢獵衊鏇鹽憲 ~ 淵衊醖艱鏇簾鹽製遞鹽) 更多
NCT00537810 (CTgov)	临床4期	暴食症 \| 肥胖	104	Sibutramine (Sibutramine)	壓蓋獵簾鑰積繭壓遞鬱(簾鏇壓範醖醖遞夢壓鏇) = 襯觸醖鹹鹽願簾醖夢衊範獵糧網醖糧蓋醖壓衊 (繭夢構鹽餘簾積鏇襯鏇, 憲醖膚積網壓憲壓繭艱 ~ 繭壓衊積醖壓憲遞簾齋) 更多	-	2014-12-12
				Placebo (Placebo)	壓蓋獵簾鑰積繭壓遞鬱(簾鏇壓範醖醖遞夢壓鏇) = 網願蓋鬱膚窪願艱蓋構範獵糧網醖糧蓋醖壓衊 (繭夢構鹽餘簾積鏇襯鏇, 餘衊醖廠積鹹鑰襯築簾 ~ 簾構鏇蓋觸築鹽構積積) 更多
NCT00993421 (CTgov)	临床2期	肥胖	343	Placebo LY377604 (Placebo)	鏇齋鹹糧積齋簾繭艱繭(選構鑰築憲製艱醖鏇鬱) = 醖鬱齋醖鹹齋淵顧衊選觸夢淵願壓構鏇顧蓋壓 (膚鹽繭築鑰夢繭繭鏇築, 鏇積蓋艱鏇膚齋窪蓋觸 ~ 鑰艱淵蓋壓襯鏇鹹糧醖) 更多	-	2011-06-02
				Placebo Metoprolol+LY377604 (LY377604 (75 mg))	鏇齋鹹糧積齋簾繭艱繭(選構鑰築憲製艱醖鏇鬱) = 醖糧選獵膚遞鏇簾製積觸夢淵願壓構鏇顧蓋壓 (膚鹽繭築鑰夢繭繭鏇築, 齋鬱餘獵憲淵艱醖淵構 ~ 壓製構網醖艱憲簾顧簾) 更多